Bioresorbable scaffolds for the treatment of coronary artery disease: Current status and future perspective

Expert Review of Medical Devices

Volumn 11, Issue 5, 2014, Pages 467-480

  Kraak, Robin P ^a   Grundeken, Maik J ^a   Koch, Karel T ^a   De Winter, Robbert J ^a   Wykrzykowska, Joanna J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

biodegradable; bioresorbable scaffold; coronary artery disease; drug eluting stents; percutaneous coronary interventions

Indexed keywords

ARTIFICIAL ORGANS; DISEASES; STENTS;

BIODEGRADABLE; BIORESORBABLE SCAFFOLDS; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; PERCUTANEOUS CORONARY INTERVENTION;

SCAFFOLDS;

BIODEGRADABLE IMPLANT; CORONARY ARTERY DISEASE; DEVICES; DRUG ELUTING STENT; FOREIGN BODY; HEART MUSCLE REVASCULARIZATION; HUMAN; PROCEDURES;

ABSORBABLE IMPLANTS; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FOREIGN BODIES; HUMANS; MYOCARDIAL REVASCULARIZATION;

EID: 84905827405     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/17434440.2014.941812     Document Type: Review

References (83)

1. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 1978; 1(8058):263
2. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979;301(2): 61-8
3. Lafont A, Guzman LA, Whitlow PL, et al. Restenosis after experimental angioplasty. Intimal, medial, and adventitial changes associated with constrictive remodeling. Circ Res 1995;76(6):996-1002
4. Sigwart U, Urban P, Golf S, et al. Emergency stenting for acute occlusion after coronary balloon angioplasty. Circulation 1988;78(5 Pt 1):1121-7
5. Urban P, Sigwart U, Golf S, et al. [Acute coronary occlusion following transluminal angioplasty: the role of an implanted parietal support via transluminal route]. Schweiz Med Wochenschr 1988;118(46): 1710-14
6. Serruys PW, De Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331(8):489-95
7. Kiemeneij F, Serruys PW, Macaya C, et al. Continued benefit of coronary stenting versus balloon angioplasty: five-year clinical follow-up of Benestent-I trial. J Am Coll Cardiol 2001;37(6):1598-603
8. Hoffmann R, Mintz GS, Popma JJ, et al. Chronic arterial responses to stent implantation: a serial intravascular ultrasound analysis of Palmaz-Schatz stents in native coronary arteries. J Am Coll Cardiol 1996;28(5):1134-9
9. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996;94(6):1247-54
10. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108(7):788-94
11. Serruys PW, Ong AT, Piek JJ, et al. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: the SPIRIT first trial. EuroIntervention 2005;1(1):58-65
12. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six-and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003; 107(1):38-42
13. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349(14):1315-23
14. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369(9562):667-78
15. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334(17):1084-9
16. Palmerini T, Biondi-Zoccai G, Della RD, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012;379(9824):1393-402
17. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011;57(11):1314-22
18. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48(1):193-202
19. Maier W, Windecker S, Kung A, et al. Exercise-induced coronary artery vasodilation is not impaired by stent placement. Circulation 2002;105(20): 2373-7
20. Serruys PW, Farooq V, Kalesan B, et al. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. JACC Cardiovasc Interv 2013;6(8)):777-89
21. Wykrzykowska JJ, Onuma Y, Serruys PW. Vascular restoration therapy: the fourth revolution in interventional cardiology and the ultimate "rosy" prophecy. EuroIntervention 2009;5(Suppl F)):F7-8
22. Waksman R. Biodegradable stents: they do their job and disappear. J Invasive Cardiol 2006;18(2):70-4
23. Onuma Y, Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularizatioñ Circulation 2011;123(7): 779-97
24. Persaud-Sharma D, McGoron A. Biodegradable Magnesium Alloys: a review of material development and applications. J Biomim Biomater Tissue Eng 2012;12: 25-39
25. Chen Y, Song Y, Zhang S, et al. Interaction between a high purity magnesium surface and PCL and PLA coatings during dynamic degradation. Biomed Mater 2011;6(2): 025005
26. Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 2000;102(4):399-404
27. Nishio S, Kosuga K, Igaki K, et al. Long-Term (10 Years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: igaki-Tamai stents. Circulation 2012;125(19):2343-53
28. Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008; 371(9616):899-907
29. Onuma Y, Dudek D, Thuesen L, et al. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv 2013;6(10): 999-1009
30. Bruining N, Tanimoto S, Otsuka M, et al. Quantitative multi-modality imaging analysis of a bioabsorbable poly-L-lactic acid stent design in the acute phase: a comparison between 2-and 3D-QCA, QCU and QMSCT-CA. EuroIntervention 2008;4(2):285-91
31. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009;373(9667):897-910
32. Tanimoto S, Bruining N, van Domburg RT, et al. Late stent recoil of the bioabsorbable everolimus-eluting coronary stent and its relationship with plaque morphology. J Am Coll Cardiol 2008;52(20):1616-20
33. Ormiston JA, Serruys PW. Bioabsorbable coronary stents. Circ Cardiovasc Interv 2009;2(3):255-60
34. Onuma Y, Serruys PW, Gomez J, et al. Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. Catheter Cardiovasc Interv 2011;78(1):3-12
35. Serruys PW, Onuma Y, Garcia-Garcia HM, et al. Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention 2014;9(11)):1271-84
36. Ormiston JA, Serruys PW, Onuma Y, et al. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Circ Cardiovasc Interv 2012;5(5):620-32
37. Serruys PW, Onuma Y, Ormiston JA, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 2010; 122(22):2301-12
38. Diletti R, Serruys PW, Farooq V, et al. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am Heart J 2012;164(5)):654-63
39. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/ NCT01425281
40. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/ NCT01023789
41. Simsek C, Magro M, Onuma Y, et al. Procedural and clinical outcomes of the Absorb everolimus-eluting bioresorbable vascular scaffold: one-month results of the Bioresorbable vascular Scaffold Evaluated At Rotterdam Cardiology Hospitals (BSEARCH). EuroIntervention 2013;10(2)): 236-40
42. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/ NCT01751906
43. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/ NCT01858077
44. Woudstra P, Grundeken MJ, Kraak RP, et al. Amsterdam Investigator- initiateD Absorb strategy all-comers trial (AIDA trial): a clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: rationale and study design. Am Heart J 2014;167(2)):133-40
45. Verheye S, Ormiston JA, Stewart J, et al. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6-and 12-month clinical and multimodality imaging results. JACC Cardiovasc Interv 2014;7(1):89-99
46. Verheye S. DESolve Nx novolimus-eluting bioresorbable coronary scaffold: first report of 1-year clinical and imaging results. In: TCT, San Francisco, CA, USA; 2013
47. Grube E. Bioabsorbable stent. The Boston Scientific and REVA technology. In: EuroPCR; Barcelona, Spain 2009
48. Costa R. 12-Month Results ReZolve Bioresorbable Coronary Scaffold: The RESTORT Trial. In: TCT; San Francisco, CA, USA; 2013
49. Erbel R, Di MC, Bartunek J, et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 2007;369(9576):1869-75
50. Waksman R, Erbel R, Di MC, et al. Earlyand long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries. JACC Cardiovasc Interv 2009;2(4):312-20
51. Haude M, Erbel R, Erne P, et al. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet 2013;381(9869):836-44
52. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/ NCT01960504
53. Lafont A, Durand E. A.R.T.: concept of a bioresorbable stent without drug elution. EuroIntervention 2009;5(Suppl F)):F83-7
54. Durand E, Lemitre M, Couty L, et al. Adjusting a polymer formulation for an optimal bioresorbable stent: a 6-month follow-up study. EuroIntervention 2012; 8(2):242-9
55. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/ NCT01761578? displayxml=true
56. Granada JF. The Amaranth stent: Design and Future Directions. In: TCT, Miami, Florida, USA. 2012
57. Granada J.F. The Amaranth PLLA based bioresorbable scaffold (ABRS): Experimental and Early Human Results. In: TCT, San Francisco, California, USA. 2013
58. Jabara R, Pendyala L, Geva S, et al. Novel fully bioabsorbable salicylate-based sirolimus-eluting stent. EuroIntervention 2009;5(Suppl F):F58-64
59. Jabara R, Chronos N, Robinson K. Novel bioabsorbable salicylate-based polymer as a drug-eluting stent coating. Catheter Cardiovasc Interv 2008;72(2):186-94
60. Jabara R. Assessment of a novel fully bio-absorbable salicylate-based sirolimus-eluting stent. In: EuroPCR Barcelona, Spain; 2009
61. Wu Y, Shen L, Wang Q, et al. Comparison of acute recoil between bioabsorbable poly-L-lactic acid XINSORB stent and metallic stent in porcine model. J Biomed Biotechnol 2012;2012:413956
62. Cottone RJ, Thatcher GL, Parker SP, et al. OrbusNeich fully absorbable coronary stent platform incorporating dual partitioned coatings. EuroIntervention 2009; 5(Suppl F)):F65-71
63. Farooq V, Serruys PW, Heo JH, et al. Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: the potential implications for clinical practice. JACC Cardiovasc Interv 2013;6(5): 523-32
64. Dzavik V, Colombo A. The absorb bioresorbable vascular scaffold in coronary bifurcations: insights from bench testing. JACC Cardiovasc Interv 2014;7(1):81-8
65. Joner M. Chronic vascular response: the view with the microscope. In: EuroPCR; Paris, France; 2014
66. Foin N, Gutierrez-Chico JL, Nakatani S, et al. Incomplete stent apposition causes high shear flow disturbances and delay in neointimal coverage as a function of strut to wall detachment distance: implications for the management of incomplete stent apposition. Circ Cardiovasc Interv 2014; 7(2):180-9
67. Bourantas CV, Papafaklis MI, Kotsia A, et al. Effect of the endothelial shear stress patterns on neointimal proliferation following drug-eluting bioresorbable vascular scaffold implantation: an optical coherence tomography study. JACC Cardiovasc Interv 2014;7(3):315-24
68. Fernandez-Rodriguez D, Brugaletta S, Otsuki S, Sabate M. Acute ABSORB bioresorbable vascular scaffold thrombosis in ST-segment elevation myocardial infarction: to stent or not to stent? EuroIntervention 2013. [Epub ahead of print]
69. Kraak RP, Hassell ME, Grundeken MJ, et al. Initial experience and clinical evaluation of the ABSORB Bioresorbable Vascular Scaffold (BVS) in real world practice.The AMC Single Centre Real World PCI Registry. EuroIntervention 2014;In press
70. van Geuns RJ. BVS Expand: 6-month results. In: EuroPCR; Paris, France; 2014
71. Brugaletta S, Radu MD, Garcia-Garcia HM, et al. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis 2012;221(1):106-12
72. Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011;364(3):226-35
73. Pu J, Mintz GS, Brilakis ES, et al. In vivo characterization of coronary plaques: novel findings from comparing greyscale and virtual histology intravascular ultrasound and near-infrared spectroscopy. Eur Heart J 2012;33(3):372-83
74. Werner M, Micari A, Cioppa A, et al. Evaluation of the biodegradable peripheral Igaki-Tamai stent in the treatment of de novo lesions in the superficial femoral artery: the GAIA study. JACC Cardiovasc Interv 2014;7(3):305-12
75. Iqbal J, Onuma Y, Ormiston J, et al. Bioresorbable scaffolds: rationale, current status, challenges, and future. Eur Heart J 2014;35(12):765-76
76. Oberhauser JP, Hossainy S, Rapoza RJ. Design principles and performance of bioresorbable polymeric vascular scaffolds. EuroIntervention 2009;5(Suppl F)):F15-22
77. Brugaletta S, Garcia-Garcia HM, Onuma Y, Serruys PW. Everolimus-eluting ABSORB bioresorbable vascular scaffold: present and future perspectives. Expert Rev. Med. Devices 2012;9(4):327-38
78. Ielasi A, Latib A, Naganuma T, et al. Early results following everolimus-eluting bioresorbable vascular scaffold implantation for the treatment of in-stent restenosis. Int J Cardiol 2014;173(3):513-14
79. Kocka V, Maly M, Tousek P, et al. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study 'Prague 19'. Eur Heart J 2014;35(12):787-94
80. Diletti R, Karanasos A, Muramatsu T, et al. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study. Eur Heart J 2014;35(12):777-86
81. Wiebe J, Mollmann H, Most A, et al. Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold. Clin Res Cardiol 2014;103(2):141-8
82. Gori T, Schulz E, Hink U, et al. Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. EuroIntervention 2014;9(9):1036-41
83. Abizaid A, Costa JR Jr, Bartorelli AL, et al. The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. EuroIntervention 2014. [Epub ahead of print]